Market Cap 131.46M
Revenue (ttm) 0.00
Net Income (ttm) -98.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 732,570
Avg Vol 823,872
Day's Range N/A - N/A
Shares Out 33.20M
Stochastic %K 52%
Beta 0.54
Analysts Strong Sell
Price Target $17.71

Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 547 9879
Address:
345 Park Avenue South, 6th Floor, New York, United States
DonCorleone77
DonCorleone77 Jun. 24 at 11:39 AM
$LXEO Lexeo announces partnership to develop therapies using non-viral RNA platform Lexeo Therapeutics announced a strategic partnership to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Combined with investment of up to $40 million from leading life-sciences investors Perceptive Xontogeny Venture Funds and venBio Partners, the partnership seeks to further revolutionize the treatment of cardiovascular diseases. The proceeds will be used to seed a new entity, the funding of which is non-dilutive to existing Lexeo shareholders. Under the terms of the agreement, the new entity will be focused on advancing research for novel RNA-based therapeutics via non-viral delivery for the treatment of genetically mediated cardiac conditions. Lexeo will contribute its expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform. As consideration for its contributions, at transaction close Lexeo has received a double-digit percentage equity position in the new entity and will be entitled to future milestone payments, royalties, and opt-in rights to certain program.
0 · Reply
Bcscoatings
Bcscoatings Jun. 20 at 6:17 PM
$PCSA low floater! Huge news out!!! Volume following it!!! Ready for take off!!! Over 132 million in volume!!! $LIXT $LXEO $SLS
1 · Reply
frontiere
frontiere Jun. 17 at 12:42 PM
When things get too asymmetric, they become a no-brainer. Especially on a long side (more caveats if short). C&Gt / Gtx / Gene editing basket is oversold, has been my thesis since Dec 2024. $VERV Verve acquired today by $LLY Eli Lilly for $10.50 cash+$3.00 CVR, vs $6.27 yesterday closing price and still below March 2024 levels. Right now Long $MGX Metagenomi since 2024 and trading actively, $SRPT Sarepta since yesterday, $LXEO Lexeo…
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 7:06 PM
$LXEO 👏👏🤞
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 2:18 PM
$LXEO members 🤞🤞
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 12:05 PM
$LXEO 🤞🤞👊
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 3:40 AM
$LXEO pick me up @ $3.89
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 6 at 7:32 PM
$LXEO just turned -4% lower to 19% (~2Mv) moments ago, 06/20 options, follow for more volatility.
0 · Reply
Capitulation_0
Capitulation_0 Jun. 6 at 5:22 PM
$LXEO Horrendous Chart.. This is not alone, the entire biotech has been hit with the big ugly short stick. It's finally showing signs of recovering. This one has 13% shorts...not uncommon and probably on the low side. Shorts had one helluva party for the past 4 years or so. It's time for bulls to take over. $XBI
0 · Reply
hitmongreen
hitmongreen Jun. 6 at 4:44 PM
$LXEO love this movement here
0 · Reply
Latest News on LXEO
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 12:05 PM EDT - 1 year ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet


Lexeo Therapeutics Proposes Terms For $126 Million IPO

Oct 31, 2023, 1:49 PM EDT - 1 year ago

Lexeo Therapeutics Proposes Terms For $126 Million IPO


Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Oct 2, 2023, 1:49 PM EDT - 1 year ago

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort


DonCorleone77
DonCorleone77 Jun. 24 at 11:39 AM
$LXEO Lexeo announces partnership to develop therapies using non-viral RNA platform Lexeo Therapeutics announced a strategic partnership to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Combined with investment of up to $40 million from leading life-sciences investors Perceptive Xontogeny Venture Funds and venBio Partners, the partnership seeks to further revolutionize the treatment of cardiovascular diseases. The proceeds will be used to seed a new entity, the funding of which is non-dilutive to existing Lexeo shareholders. Under the terms of the agreement, the new entity will be focused on advancing research for novel RNA-based therapeutics via non-viral delivery for the treatment of genetically mediated cardiac conditions. Lexeo will contribute its expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform. As consideration for its contributions, at transaction close Lexeo has received a double-digit percentage equity position in the new entity and will be entitled to future milestone payments, royalties, and opt-in rights to certain program.
0 · Reply
Bcscoatings
Bcscoatings Jun. 20 at 6:17 PM
$PCSA low floater! Huge news out!!! Volume following it!!! Ready for take off!!! Over 132 million in volume!!! $LIXT $LXEO $SLS
1 · Reply
frontiere
frontiere Jun. 17 at 12:42 PM
When things get too asymmetric, they become a no-brainer. Especially on a long side (more caveats if short). C&Gt / Gtx / Gene editing basket is oversold, has been my thesis since Dec 2024. $VERV Verve acquired today by $LLY Eli Lilly for $10.50 cash+$3.00 CVR, vs $6.27 yesterday closing price and still below March 2024 levels. Right now Long $MGX Metagenomi since 2024 and trading actively, $SRPT Sarepta since yesterday, $LXEO Lexeo…
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 7:06 PM
$LXEO 👏👏🤞
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 2:18 PM
$LXEO members 🤞🤞
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 12:05 PM
$LXEO 🤞🤞👊
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 3:40 AM
$LXEO pick me up @ $3.89
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 6 at 7:32 PM
$LXEO just turned -4% lower to 19% (~2Mv) moments ago, 06/20 options, follow for more volatility.
0 · Reply
Capitulation_0
Capitulation_0 Jun. 6 at 5:22 PM
$LXEO Horrendous Chart.. This is not alone, the entire biotech has been hit with the big ugly short stick. It's finally showing signs of recovering. This one has 13% shorts...not uncommon and probably on the low side. Shorts had one helluva party for the past 4 years or so. It's time for bulls to take over. $XBI
0 · Reply
hitmongreen
hitmongreen Jun. 6 at 4:44 PM
$LXEO love this movement here
0 · Reply
Capitulation_0
Capitulation_0 Jun. 4 at 5:21 PM
$LXEO walking up.. let's go!
0 · Reply
Capitulation_0
Capitulation_0 Jun. 4 at 4:59 PM
$LXEO Investors didn't like the offering but perhaps, that's behind it now. I see some real strength. AA
0 · Reply
JoshThe3rd
JoshThe3rd May. 29 at 11:28 PM
$TSHA Market is skiddish on giving premium to Gtx Cos right now. $LXEO had an 80M offering at 2.82$ and barely moved. Value will be realized here, but it may not be as fast as people expect. Remember we are in high rate macro environment (which is bearish for biotech), where the good science + good management + good funding will win out until better days.
0 · Reply
hitmongreen
hitmongreen May. 27 at 4:50 PM
$LXEO buying
1 · Reply
HorsePicks
HorsePicks May. 27 at 11:45 AM
$LXEO Lexeo Therapeutics Announces $80M Equity Financing To Further Advance Development Of Transformative Genetic Medicines For Cardiovascular Diseases, Financing Led By Frazier Life Sciences And Janus Henderson Investors With Participation From New And Existing Investors
0 · Reply
ahTony
ahTony May. 27 at 11:44 AM
0 · Reply
DonCorleone77
DonCorleone77 May. 27 at 11:40 AM
$LXEO Lexeo prices 20.8M shares at $2.8825 in private placement Lexeo Therapeutics has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares of its common stock or, in lieu thereof, to certain investors, pre-funded warrants to purchase 6,963,556 shares of Common Stock, in a private placement. Each full Share will be accompanied by a warrant to purchase one-half of a share of Common Stock. The purchase price for each Share and accompanying Common Warrant will be $2.8825. Lexeo anticipates the gross proceeds from the private placement to be approximately $80M, before deducting any offering related expenses. The private placement is expected to close on May 28, subject to customary closing conditions. The Pre-Funded Warrants will have an exercise price of $0.0001 per share until exercised in full, and the Common Warrants will have an exercise price of $2.82 per share and expire on May 28, 2029. The private placement was co-led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors, including Adar1 Capital Management, Affinity Healthcare Fund, Ally Bridge Group, Coastlands Capital, Surveyor Capital, Vestal Point Capital, and Woodline Partners. J.P. Morgan and Oppenheimer & Co. acted as co-lead placement agents for the transaction. Baird also acted as placement agent. Lexeo intends to use net proceeds from the private placement to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes. The proceeds from this private placement, combined with current cash, cash equivalents and marketable securities are expected to fund Lexeo's operating and capital expenditures into 2028.
0 · Reply
garygb
garygb May. 26 at 2:51 AM
$LXEO Great buy at this price.
0 · Reply
SportsBetz
SportsBetz May. 22 at 1:04 PM
$VRTX $CRSP $LXEO $RCKT Some seriously good news for gene therapy tickers. from Phoenix Biotech on X @biotechanalyst
1 · Reply
hitmongreen
hitmongreen May. 21 at 8:02 PM
$LXEO buying heavily
0 · Reply
_www_larval_com_
_www_larval_com_ May. 21 at 7:52 PM
$WOLF 5%[-59%] $UOKA -4%[-19%] $LXEO 3%[-14%] $BTM 3%[3%] $SYTA 3%[-37%] most notable movement into the final minutes of trading.
0 · Reply
SportsBetz
SportsBetz May. 16 at 2:04 PM
$LXEO I don't hate it!
0 · Reply